• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用4-1BB(CD137)刺激可通过诱导供体CD4 + T细胞的活化诱导细胞死亡来抑制慢性移植物抗宿主病。

Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.

作者信息

Kim Juyang, Choi Woon S, La Soojin, Suh Jae-Hee, Kim Byoung-Sam, Cho Hong R, Kwon Byoung S, Kwon Byungsuk

机构信息

The Immunomodulation Research Center, University of Ulsan, San29, Mukeo-dong, Nam-ku, Ulsan 680-749, Republic of Korea.

出版信息

Blood. 2005 Mar 1;105(5):2206-13. doi: 10.1182/blood-2004-06-2080. Epub 2004 Nov 2.

DOI:10.1182/blood-2004-06-2080
PMID:15522958
Abstract

4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily, is a costimulator for activated T cells. Previous studies have established that treatment with agonistic anti-4-BB monoclonal antibody (3H3) is effective in reversing the progression of spontaneous systemic lupus erythematosus. Its therapeutic effect is mediated by suppression of autoantibody production. In this report, we show that a single injection of 3H3 blocks chronic graft-versus-host disease (cGVHD) in the parent-into-F1 model. In particular, donor CD4+ T cells are rapidly eliminated from host spleens by activation-induced cell death after 4-1BB triggering. Since donor CD4+ T cells are required for the development of cGVHD, and 3H3-mediated inhibition of autoantibody production occurs without donor CD8+ T cells, 3H3 blocks cGVHD by preventing alloreactive donor CD4+ T cells from activating host B cells. Importantly, 3H3 treatment can reverse the progression of advanced cGVHD. Our findings indicate that agonistic anti-4-1BB monoclonal antibody has potential as an immunotherapeutic agent for preventing and treating cGVHD.

摘要

4-1BB是肿瘤坏死因子(TNF)受体超家族的成员,是活化T细胞的共刺激分子。先前的研究表明,用激动性抗4-1BB单克隆抗体(3H3)治疗可有效逆转自发性系统性红斑狼疮的进展。其治疗效果是通过抑制自身抗体产生介导的。在本报告中,我们表明单次注射3H3可在亲代到F1模型中阻断慢性移植物抗宿主病(cGVHD)。特别是,在4-1BB触发后,供体CD4+ T细胞通过活化诱导的细胞死亡从宿主脾脏中迅速清除。由于cGVHD的发生需要供体CD4+ T细胞,且3H3介导的自身抗体产生抑制在没有供体CD8+ T细胞的情况下也会发生,因此3H3通过阻止同种反应性供体CD4+ T细胞激活宿主B细胞来阻断cGVHD。重要的是,3H3治疗可以逆转晚期cGVHD的进展。我们的研究结果表明,激动性抗4-1BB单克隆抗体具有作为预防和治疗cGVHD的免疫治疗剂的潜力。

相似文献

1
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.用4-1BB(CD137)刺激可通过诱导供体CD4 + T细胞的活化诱导细胞死亡来抑制慢性移植物抗宿主病。
Blood. 2005 Mar 1;105(5):2206-13. doi: 10.1182/blood-2004-06-2080. Epub 2004 Nov 2.
2
Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.4-1BB(CDw137)的结扎调节异基因骨髓移植受者的移植物抗宿主病、移植物抗白血病和移植物排斥反应。
J Immunol. 2001 Mar 1;166(5):3174-83. doi: 10.4049/jimmunol.166.5.3174.
3
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.共刺激T细胞受体CD137的激活可逆转狼疮易感NZB×NZW F1小鼠的急性疾病。
J Clin Invest. 2003 May;111(10):1505-18. doi: 10.1172/JCI17662.
4
Prevention of chronic graft-versus-host disease by stimulation with glucocorticoid-induced TNF receptor.通过糖皮质激素诱导的肿瘤坏死因子受体刺激预防慢性移植物抗宿主病
Exp Mol Med. 2006 Feb 28;38(1):94-9. doi: 10.1038/emm.2006.11.
5
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.给予激动型抗4-1BB单克隆抗体可改善实验性自身免疫性脑脊髓炎。
J Immunol. 2002 Feb 1;168(3):1457-65. doi: 10.4049/jimmunol.168.3.1457.
6
Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor.通过糖皮质激素诱导的TNF受体的体内连接,将同种抗原特异性CD8 + T细胞无反应性转化为CD8 + T细胞致敏。
J Immunol. 2006 May 1;176(9):5223-31. doi: 10.4049/jimmunol.176.9.5223.
7
Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.针对T细胞活化分子CD137(白细胞介素-A或4-1BB)的单克隆抗体可阻断严重联合免疫缺陷小鼠中人类淋巴细胞介导的肿瘤异种移植抑制作用。
J Immunother. 2000 May-Jun;23(3):362-8. doi: 10.1097/00002371-200005000-00009.
8
Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.与输注CD137特异性单克隆抗体相比,使用表达CD137单链Fv的全细胞肿瘤疫苗可使CD137连接的抗肿瘤功效最大化。
Mol Cancer Ther. 2006 Jan;5(1):149-55. doi: 10.1158/1535-7163.MCT-05-0206.
9
Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.抗CD137抗体在自身免疫性疾病和癌症治疗中的应用。
Immunol Res. 2004;29(1-3):197-208. doi: 10.1385/IR:29:1-3:197.
10
CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.CD137介导的T细胞共刺激可终止易患系统性红斑狼疮的NZB/NZW F1小鼠现有的自身免疫性疾病。
Ann N Y Acad Sci. 2003 Apr;987:230-5. doi: 10.1111/j.1749-6632.2003.tb06052.x.

引用本文的文献

1
Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.靶向 4-1BB 和 PD-L1 可诱导 B 细胞淋巴瘤产生强大而持久的抗肿瘤免疫。
Front Immunol. 2022 Dec 5;13:1004475. doi: 10.3389/fimmu.2022.1004475. eCollection 2022.
2
The promise of CD4FoxP3 regulatory T-cell manipulation : applications for allogeneic hematopoietic stem cell transplantation.CD4FoxP3 调节性 T 细胞操纵的前景:同种异体造血干细胞移植的应用。
Haematologica. 2019 Jul;104(7):1309-1321. doi: 10.3324/haematol.2018.198838. Epub 2019 Jun 20.
3
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
移植环境中靶向共抑制和共刺激途径的研究进展:癌症免疫治疗的阴阳两面
Immunol Rev. 2017 Mar;276(1):192-212. doi: 10.1111/imr.12523.
4
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.共刺激和共抑制反应中的肿瘤坏死因子受体超家族
Immunity. 2016 May 17;44(5):1005-19. doi: 10.1016/j.immuni.2016.04.019.
5
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.CD137和CD137L信号是1型细胞介导免疫反应的主要驱动因素。
Oncoimmunology. 2015 Nov 11;5(4):e1113367. doi: 10.1080/2162402X.2015.1113367. eCollection 2016 Apr.
6
Human and mouse CD137 have predominantly different binding CRDs to their respective ligands.人和鼠的 CD137 与其各自配体的结合 CRD 主要不同。
PLoS One. 2014 Jan 21;9(1):e86337. doi: 10.1371/journal.pone.0086337. eCollection 2014.
7
Gene silencing of 4-1BB by RNA interference inhibits acute rejection in rats with liver transplantation.RNA 干扰抑制 4-1BB 基因沉默可抑制肝移植大鼠急性排斥反应。
Biomed Res Int. 2013;2013:192738. doi: 10.1155/2013/192738. Epub 2013 Jan 31.
8
Advances in targeting cell surface signalling molecules for immune modulation.靶向细胞表面信号分子进行免疫调节的研究进展。
Nat Rev Drug Discov. 2013 Feb;12(2):130-46. doi: 10.1038/nrd3877.
9
CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.CD137 配体激活的小胶质细胞通过活性氧诱导少突胶质细胞凋亡。
J Neuroinflammation. 2012 Jul 16;9:173. doi: 10.1186/1742-2094-9-173.
10
Anti-CD137 mAb Deletes Both Donor CD4 and CD8 T Cells in Acute Graft-versus-host Disease.抗 CD137 mAb 在急性移植物抗宿主病中消除供体 CD4 和 CD8 T 细胞。
Immune Netw. 2011 Dec;11(6):428-30. doi: 10.4110/in.2011.11.6.428. Epub 2011 Dec 31.